Dupont Capital Management Corp Buys 8,146 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

Dupont Capital Management Corp increased its stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGOGet Rating) by 39.9% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 28,586 shares of the company’s stock after acquiring an additional 8,146 shares during the quarter. Dupont Capital Management Corp’s holdings in Organogenesis were worth $93,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Ameritas Investment Partners Inc. boosted its position in shares of Organogenesis by 80.1% during the first quarter. Ameritas Investment Partners Inc. now owns 5,386 shares of the company’s stock worth $41,000 after acquiring an additional 2,396 shares during the last quarter. KBC Group NV purchased a new stake in Organogenesis during the second quarter valued at $27,000. Point72 Hong Kong Ltd raised its stake in Organogenesis by 245.7% during the second quarter. Point72 Hong Kong Ltd now owns 6,015 shares of the company’s stock valued at $29,000 after purchasing an additional 4,275 shares in the last quarter. Lazard Asset Management LLC raised its stake in Organogenesis by 3,808.2% during the first quarter. Lazard Asset Management LLC now owns 9,106 shares of the company’s stock valued at $69,000 after purchasing an additional 8,873 shares in the last quarter. Finally, Vantage Consulting Group Inc purchased a new stake in Organogenesis during the second quarter valued at $51,000. Institutional investors own 47.03% of the company’s stock.

Analyst Ratings Changes

Separately, BTIG Research downgraded shares of Organogenesis from a “buy” rating to a “neutral” rating in a research note on Thursday, November 10th.

Organogenesis Price Performance

Organogenesis stock opened at $2.56 on Thursday. The company has a market cap of $335.14 million, a price-to-earnings ratio of 5.57 and a beta of 1.60. The firm’s fifty day moving average is $2.67 and its 200 day moving average is $3.61. The company has a quick ratio of 2.31, a current ratio of 2.58 and a debt-to-equity ratio of 0.26. Organogenesis Holdings Inc. has a 52-week low of $2.23 and a 52-week high of $9.27.

Organogenesis (NASDAQ:ORGOGet Rating) last announced its earnings results on Wednesday, November 9th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.02). Organogenesis had a net margin of 13.06% and a return on equity of 28.74%. The firm had revenue of $116.86 million during the quarter, compared to analysts’ expectations of $121.40 million. Sell-side analysts forecast that Organogenesis Holdings Inc. will post 0.13 EPS for the current fiscal year.

Organogenesis Company Profile

(Get Rating)

Organogenesis Holdings Inc, a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved.

See Also

Want to see what other hedge funds are holding ORGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organogenesis Holdings Inc. (NASDAQ:ORGOGet Rating).

Institutional Ownership by Quarter for Organogenesis (NASDAQ:ORGO)

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.